Virus-Like-Vaccines against HIV. - Test2 - elhamkhani - TriplyDB

Virus-Like-Vaccines against HIV.

Virus-Like-Vaccines against HIV.

http://www.wikidata.org/entity/Q50034030

about

Virus-Like-Vaccines against HIV.

http://www.wikidata.org/entity/Q50034030

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Virus-Like-Vaccines against HIV.

@en

Virus-Like-Vaccines against HIV.

@nl

type

label

Virus-Like-Vaccines against HIV.

@en

Virus-Like-Vaccines against HIV.

@nl

prefLabel

Virus-Like-Vaccines against HIV.

@en

Virus-Like-Vaccines against HIV.

@nl

P1433

Q50034030-6164C4CF-2891-4655-83EE-84CCF6C01F83

P1476

Q50034030-796C064E-F670-4587-91A4-E64F71F94A26

P2093

Q50034030-B111424F-AB1B-46F7-AFA8-564C6C2C51D5

Q50034030-CC9FC996-1EE4-43DE-8330-1A7FC5B9A2CF

P2860

Q50034030-060357B8-854E-41C2-8872-0174EE0228C6

Q50034030-097CC566-3334-47B7-B7E6-596B89AA0A18

Q50034030-0A813353-EBF4-4653-A6F0-90FFC0063EA5

Q50034030-174E5507-4CA8-4098-83DE-831DD943C685

Q50034030-17F49F2F-4E3D-405A-9C1F-AD10E9F6BD91

Q50034030-1906078F-2B73-4423-89B3-0E5D86EB4E2D

Q50034030-1A9811C9-D3DE-4B6D-93C1-59CE626252E8

Q50034030-23EC1249-E7E7-4A4B-B869-1F8657555783

Q50034030-24984EE6-E67D-4E22-91BE-D71BC622D2CC

Q50034030-25C4DACC-1F5E-4E63-BFE8-C4CED8C9CDAB

P31

Q50034030-FAD67BB5-80EF-4C50-9535-DB1265108D4D

P356

Q50034030-1D067B97-218B-4424-A6E6-A974121AAE6C

P433

Q50034030-9DCE218C-3519-4451-BAA1-70EEA8D0C77F

P478

Q50034030-ACDAB57B-3B27-42C0-A4D3-C666063DD110

P50

Q50034030-BDCA1898-D013-4E28-9CBC-848F4865410C

P577

Q50034030-99A7E371-BC39-4878-AD28-A8A5ADFB60CF

P698

Q50034030-1D63E8FC-7595-4845-8DD8-1DE84D5DB49B

P932

Q50034030-364F859A-8247-4D1C-ADE2-EE4AA511E6EA

P356

VACCINES6010010

P1433

P1476

Virus-Like-Vaccines against HIV.

@en

P2093

Anne-Marie C Andersson

http://www.w3.org/2001/XMLSchema#string

Melanie Schwerdtfeger

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand

HIV-Host Interactions: Implications for Vaccine Design

Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site

The Immune Response in Measles: Virus Control, Clearance and Protective Immunity

Live attenuated vaccines: Historical successes and current challenges

Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

P31

scholarly article

P356

10.3390/VACCINES6010010

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Peter Johannes Holst

P577

2018-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29439476

http://www.w3.org/2001/XMLSchema#string

P932

5874651

http://www.w3.org/2001/XMLSchema#string